Regeneron (REGN) performed poorly. REGN stock entered a prolonged downtrend, despite no major news that would explain the decline. Last Friday, May 30, Regeneron and its drug development partner ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron Pharmaceuticals ... affordability challenges. Still, EYLEA HD posted a 54% increase in U.S. sales to $307 million, partially offsetting the decline. Dupixent remains a growth driver ...

Regeneron’s shares have lost 14.1% year to date compared with the industry’s decline of 4.7%. Eylea’s sales in the United States plunged 39% year over year to $736 million, primarily due to ...

Regeneron posted its Eylea updates as the company reported ... cholesterol med Praluent, suffered a 19% sales decline to $57 million in the U.S. The company also shares sales on the immunology ...

Sales of oncology drug, Libtayo, also missed estimates. Shares are trading down in response to lower-than-expected results. Regeneron’s shares have lost 14.1% year to date compared with the industry’s ...

To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. The initial uptake of Eylea HD has been strong as Eylea patients transition to the higher dose. Sales of Eylea ...

Morningstar brands and products Company Portfolio ...

The drug's sales in the fourth quarter of 2024 were significantly below analyst expectations, contributing to the stock's decline. Eylea HD, the higher dose of Regeneron's widely used eye treatment, ...

The drug's sales in the fourth quarter of 2024 were significantly below analyst expectations, contributing to the stock's decline. Eylea HD, the higher dose of Regeneron's widely used eye ...